The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy and the agents, both commercially available and investigational, used to treat malignant diseases.
The views expressed in this article are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense, or the United States Government.
Get full access to this article
View all access options for this article.
References
1.
WiedemannG.J., RobinsH.I., GutscheS.. Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma. Eur J Cancer.1996; 32A(5): 888–892.
2.
WestermannA.M., WiedemannG.J., JagerE.. A systemic Hyperthermia Oncologic Working Trial. Ifosfamide, carboplatin, and etoposide combined with 41.8°C whole-body hyperthermia for metastatic soft tissue sarcoma. Oncology.2003; 64(4): 312–321.
3.
Van WinkleP., AngiolilloA., KrailoM.. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer.2005; 44(4): 338–347.
4.
KungF.H., DesaiS.J., DickermanJ.D.. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol.1995; 17(3): 265–269.
5.
LokichJ., AndersonN., MooreC., BernM., CocoF., DowE.Pilot study of ambulatory delivery of a multidrug regimen: ifosfamide, carboplatin, and etoposide (ICE). J Infus Chemother.1996; 6(1): 39–42.
6.
FieglM., SchlemmerM., WendtnerC.M., Abdel-RahmanS., FahnW., IsselsR.D.Ifosfamide, carboplatin and etoposide (ice) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Int J Hyperthermia.2004; 20(6): 661–670.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44: 124–130.
9.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
American Society of Clinical Oncology; KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 [published correction appears in J Clin Oncol. 2006; 24(33): 5341–5342]. J Clin Oncol.2006; 24(18): 2932–2947.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
14.
du BoisA., VachW., KiechleM., Cramer-GiraudU., MeerpohlH.G.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(Suppl 1): 46–50.
15.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
16.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
17.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
18.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
19.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
20.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
21.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced Hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
24.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
27.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–405.
28.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
29.
AronoffG.R., BennettW.M., BernsJ.S.. Drug Prescribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
30.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
31.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
32.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
